Why SOPHiA GENETICS SA’s (SOPH) Stock Is Down 5.08%
As of Wednesday, September 09, SOPHiA GENETICS SA’s SOPH share price has dipped by 5.08%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.
Commentary & Analysis
Why SOPHiA GENETICS SA’s (SOPH) Stock Is Down 5.76%
As of Wednesday, September 02, SOPHiA GENETICS SA’s SOPH share price has dipped by 5.76%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why SOPHiA GENETICS SA’s (SOPH) Stock Is Down 6.73%
As of Friday, August 28, SOPHiA GENETICS SA’s SOPH share price has dipped by 6.73%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Is SOPHiA GENETICS SA (SOPH) Overvalued?
We dive into why SOPHiA GENETICS SA (SOPH) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
Why SOPHiA GENETICS SA’s (SOPH) Stock Is Down 5.34%
As of Wednesday, August 05, SOPHiA GENETICS SA’s SOPH share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | SOPH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $726.1 | $302.4 | 41% |
|
| Shares Out (Mil) | 73.8 | 52.9 | 56% |
|
| Institutional Ownership | 84.7% | 79.7% | 53% |
|
| Float (Mil) | 65.4 | 44.4 | 53% |
|
| Beta | 0.92 | 1.21 | 55% |
|
| Avg Daily Volume (000s) | 760 | 393 | 66% |
|
| Price Change (52-week) |
164.1% | 46.8% | 97% |
|
| Growth | SOPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.2% | 12.8% | 84% |
|
| Net Income (5yr) | (15.0%) | 5.4% | 25% |
|
| EPS (5yr) | (4.7%) | 15.5% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.1%) | (15.5%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.200) | ($0.850) | ($0.500) | |
| Month Ago EPS | ($0.200) | ($0.850) | ($0.500) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.190) | ($0.780) | ($0.560) | |
| Year/Year Chg | (34.0%) | (27.4%) | (69.2%) | |
| Financials | SOPH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $86 | $192 | 25% |
|
| Net Income (TTM) (Mil) | ($81) | ($9) | 13% |
|
| EPS (TTM) | ($1.160) | ($0.500) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($40) | $9 | 11% |
|
| Net Cash Flow (TTM) (Mil) | $13 | $3 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $59 | $16 | 40% |
|
| Enterprise Value (Q1) (Mil) | $602 | $239 | 36% |
|
| Valuation | SOPH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.70 | 1.28 | 89% |
|
| P/E | na | 40.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 2.4 | na |
|
| Ratios | SOPH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 66.6% | 61.6% | 78% |
|
| Net Margin | (93.9%) | (22.6%) | 8% |
|
| ROA | (43.0%) | (17.9%) | 13% |
|
| ROE | (101.2%) | (2.1%) | 9% |
|
| Liabilities to Assets | 58.1% | 31.9% | 51% |
|
| F-Score | 3 | 4 | 18% |
|
SOPHiA GENETICS SA did not pass any screens on 9/17/2026.
